Prostate cancer drug combo fails to show benefit in Late-Stage trial

NCT ID NCT04934722

Completed Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 24 times

Summary

This study tested whether adding the immunotherapy drug pembrolizumab to standard hormone therapy (enzalutamide plus ADT) could help men with metastatic hormone-sensitive prostate cancer live longer or delay cancer growth. The trial enrolled 186 participants in China. Unfortunately, the study was stopped early because the combination did not show enough benefit to continue. Participants were offered standard care instead.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

2nd Affil Hosp of Zhejiang University College of Medicine ( Site 0808)

Hangzhou, Zhejiang, 310009, China
Beijing Cancer Hospital ( Site 0802)

Beijing, Beijing Municipality, 100142, China
Chongqing Cancer Hospital ( Site 0815)

Chongqing, Chongqing Municipality, 400030, China
Harbin Medical University Cancer Hospital ( Site 0822)

Harbin, Heilongjiang, 150081, China
Henan Cancer Hospital ( Site 0818)

Zhengzhou, Henan, 450008, China
Hubei Cancer Hospital ( Site 0833)

Wuhan, Hubei, 430079, China
Hunan Cancer Hospital ( Site 0817)

Changsha, Hunan, 410013, China
Nanjing Drum Tower Hospital ( Site 0811)

Nanjing, Jiangsu, 210008, China
Ningbo First Hospital-Urology (0835)

Ningbo, Zhejiang, 315010, China
Peking University First Hospital ( Site 0800)

Beijing, Beijing Municipality, 100034, China
Renji Hospital Shanghai Jiaotong University School of Medicine ( Site 0807 )

Shanghai, Shanghai Municipality, 200127, China
Southern Medical University Nanfang Hospital ( Site 0838)

Guangzhou, Guangdong, 510515, China
Sun Yat Sen Memorial Hospital (Site # 0819)

Guangzhou, Guangdong, 510220, China
Sun Yat-Sen University Cancer Center ( Site 0825)

Guangzhou, Guangdong, 510060, China
The 1st Affil Hosp of College of Medicine, Zhejiang Univ ( Site 0830)

Hangzhou, Zhejiang, 310009, China
The First Affiliated Hospital of Guangzhou Medical University-Urology ( Site 0638)

Guangzhou, Guangdong, 510120, China
The First Affiliated Hospital of Nanchang University ( Site 0821)

Nanchang, Jiangxi, 330006, China
The First Affiliated Hospital of Wenzhou Medical University ( Site 0834)

Wenzhou, Zhejiang, 325000, China
The First Affiliated Hospital of Xiamen University (Site 0816)

Xiamen, Fujian, 361000, China
The Second Affiliated Hosp of Xi'an Jiaotong Univ College of Medicine ( Site 0831)

Xi'an, Shaanxi, 710004, China
The first affiliated Hospital of Xi an Jiaotong University ( Site # 0812)

Xi’an, Shanxi, 710061, China
Tianjin Medical University Cancer Institute & Hospital ( Site 0804 )

Tianjin, Tianjin Municipality, 300000, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 0829)

Wuhan, Hubei, 430000, China
Zhejiang Provincial People's Hospital ( Site 0809)

Hangzhou, Zhejiang, 310014, China

Conditions

Explore the condition pages connected to this study.

METASTATIC HORMONE-SENSITIVE PROSTATE CANCER